Pipeline Insight: Breast Cancer - A diverse and increasingly crowded pipeline

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2006-07-27

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Breast cancer is the leading cause of cancer-related mortality among women worldwide. In 2006, more than 447,000 cases of the disease are expected to be diagnosed in the seven major pharmaceutical markets. High unmet needs still persist for this tumor type. Despite recent drug approvals in the adjuvant and metastatic setting, the overall survival remains below five years.


Scope

  • Overview of breast cancer and the current treatment options, including profiles and analysis of existing drugs
  • Insightful analysis of clinical trial data for late-phase drugs in development for breast cancer
  • Future global sales of key pipeline drugs for breast cancer to 2016, including their clinical/research and commercial attractiveness
  • Datamonitor's assessment of the clinical and commercial potential of the drugs currently in development for breast cancer


    • Report Highlights
    There are at least 144 candidates in the breast cancer pipeline of which, 26% are molecular targeted therapeutics (MTTs). Due to the cytostatic nature of several MTTs, significant tumor regressions will likely be achieved when combined with cytotoxics. As cytotoxics comprise one-third of the pipeline, they will remain the backbone of treatment.

    Datamonitor believes Genentech/Roche's Avastin (bevacizumab) will earn blockbuster status within the breast cancer market. Unlike Herceptin, Avastin is not limited to HER-2 positive tumors and will have a major impact on first-line metastatic disease. Avastin will dominate the breast cancer market with 2016 sales approaching $1.5bn.

    GlaxoSmithKline's' Tykerb (lapatinib) will expand treatment options for HER-2 positive, Herceptin-refractory, locally advanced and metastatic patients, with approval likely by early-2007. As an estimated 40% of patients are Herceptin-refractory, Tykerb's sales could reach over $500m by 2016 in this setting alone.


    Reasons to Purchase

  • Assess opportunities and risks in the breast cancer market by analyzing the clinical and commercial attractiveness of key agents
  • Evaluate the potential of your product in the breast cancer market by examining key pipeline drug sales forecasts
  • Determine the commercial impact of new molecular-targeted agents entering the breast cancer market and their effects on current treatment paradigms

    • Table of Contents

    Other users found this report page using the following search terms: breast cancer breast cancer metastatic sutent market trial e7389 iressa phase pipeline

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.